Efficacy and safety of add-on mirogabalin to conventional therapy for the treatment of peripheral neuropathic pain after thoracic surgery: the multicenter, randomized, open-label ADMIT-NeP study

Table 3 Patients with S-LANSS score ≥ 12 (mITT population)

	Mirogabalin add-on group			Conventional treatment group			Fisher P value^b
	n	Patients with S-LANSS score of ≥ 12	McNemar P value^a	n	Patients with S-LANSS score of ≥ 12	McNemar P value^a	Fisher P value^b
Baseline	60	30 (50.0)	-	65	27 (41.5)	-	0.373
Week 2	54	26 (48.1)	1.000	59	27 (45.8)	0.690	0.852
Week 4	52	22 (42.3)	0.690	56	19 (33.9)	0.327	0.430
Week 8	50	10 (20.0)	0.003	53	16 (30.2)	0.134	0.264

Data are n (%) mITT modified intention-to-treat, S-LANSS Self-administered Leeds Assessment of Neuropathic Symptoms and Signs
^avs. baseline
^bvs. the conventional treatment group

ISSN: 1471-2407